Daily Intelligence Brief
Depo-Provera, Hair Relaxer Pace 258 New Federal Filings as Baby Food Metals Resurfaces in Florida Courts
The Depo-Provera Products Liability Litigation (MDL 3140) and Hair Relaxer Marketing, Sales Practices, and Products Liability Litigation (MDL 3060) combined for 109 new federal complaints over the past week, maintaining their dominance of mass tort dockets even as both litigations face critical inflection points — Depo-Provera's December bellwether selection and Hair Relaxer's pending Daubert ruling on general causation. The Uber Technologies, Inc., Passenger Sexual Assault Litigation (MDL 3084) added 22 filings as its second bellwether trial opened April 13, while the Baby Food Products Liability Litigation (MDL 3101) showed unexpected velocity with four new cases in Florida federal courts, suggesting renewed plaintiff-side interest in heavy metals claims that had slowed considerably after 2023's initial wave. Notably, the Paragard IUD Products Liability Litigation (MDL 2974) registered four filings in the Northern District of Georgia, its first significant cluster in months, as that MDL approaches its own bellwether calendar.Zantac Litigation Sees Rare Post-Remand Filing as Ranitidine Claims Persist in Pennsylvania
A single new complaint in the Zantac (Ranitidine) Products Liability Litigation (MDL 2924) (S.D. Fla., Judge Robin L. Rosenberg) marks a rare post-remand filing in a litigation that the JPML dissolved in August 2022 after the MDL court's comprehensive Daubert exclusion of plaintiff experts. The filing in Pennsylvania Eastern District (2:26-cv-02362) suggests some plaintiffs continue to pursue ranitidine cancer claims in federal court despite the MDL's dismantling, likely relying on state-court expert admissibility standards or alternate theories that survived the federal causation ruling. The development carries limited precedential weight but signals persistent claimant demand and potential fragmentation into state courts where expert standards vary. Defendants including Sanofi and GSK face no active MDL exposure but must monitor whether scattered federal filings indicate coordinated state-court activity or isolated holdout litigation.Sioux City Council Poised to Approve $161K PFAS Settlement as Municipal Liability Proliferates
The Sioux City Council is scheduled to vote on a $161,000 settlement resolving claims against the municipality for PFAS contamination, reflecting the accelerating shift of "forever chemicals" liability from industrial defendants to downstream water systems and municipalities caught between cleanup obligations and limited recourse. The settlement, reported April 12, follows a pattern of municipal PFAS resolutions that have totaled hundreds of millions nationally as cities confront EPA enforcement actions and citizen suits under the Safe Drinking Water Act. For plaintiffs' attorneys, municipal settlements represent a secondary revenue stream distinct from the manufacturer-focused AFFF Products Liability Litigation (MDL 2873) and emerging drinking water MDLs, with shorter case timelines and lower defense costs. The Sioux City vote underscores how PFAS liability continues to metastasize across the supply chain even as the primary MDL approaches its own bellwether trials.Generated by LexGenius Feed. Signals sourced from PACER federal court dockets, FDA/OpenFDA adverse event database, Federal Register, PubMed, and Google News.
